- Details
- Description
Packaging Size:
30t/bottle
Strength:
15mg&45mg
Composition:
Dacomitinib
Treatment:
EGFR exon 19 deletions or exon 21 (L858R) substitution mutations non-small cell lung cancer (NSCLC)
Form:
Tablet
Brand:
LuciDac
Quantity Unit:
15mg*30T/Bottle&45mg*30T/Bottle
Manufacturer:
Lucius Pharmaceuticals (Lao) Co.,Ltd
INDICATIONS AND USAGE
Dacomitinib is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.
DOSAGE AND ADMINISTRATION
Recommended Dosage: 45 mg orally once daily with or without food.
